Patient Characteristics (n = 91)
| Characteristic | Value |
| Age (y) | 37–78 (median, 52) |
| Sex | Male, 90; female, 1 |
| Smoking | Yes, 80; no, 11 |
| Betel nut squid | Yes, 64; no, 27 |
| Alcoholism | Yes, 59; no, 32 |
| Primary lesion site | |
| Oropharynx | 49 |
| Hypopharynx | 42 |
| American Joint Committee on Cancer stage (24) | III, 10; IV, 81 |
| T stage | T1, 7; T2, 36; T3, 27; T4, 21 |
| N stage | N1, 15; N2, 70; N3, 6 |
| Total radiation dose (Gy) | 66–74 (median, 70) |
| Overall radiation interval (d) | 43–82 (median, 53) |
| Concurrent chemotherapy or drug | |
| Cisplatin-based | 70 |
| Weekly cetuximab | 14 |
| None | 7 |
| PET/CT-related parameters | |
| N-SUVmax | 6.5 ± 4.4 (1.2–28.5); median, 6.1 |
| N-MTV2.5 (mL) | 11.5 ± 25.6 (0.1–178); median, 3.0 |
| N-MTV40% (mL) | 10.0 ± 18.4 (1.0–153); median, 5.1 |
| N-MTV50% (mL) | 7.1 ± 14.2 (0.5–119); median, 3.6 |
| N-TLG40% (g) | 112.8 ± 168.5 (0–855.3); median, 38.0 |
| N-TLG50% (g) | 87.3 ± 134.9 (0–664.7); median, 29.0 |
| CT-based volume parameters | |
| N-GTV (mL) | 18.1 ± 27.8 (1–185); median, 8.9 |
| Maximal diameter (cm) | 2.9 ± 1.9 (1.1–10.8); median, 2.4 |
| Central necrosis | 51/91 |
| Follow up (mo) | 3–69 (median, 18) |
N-MTV40% = pretreatment nodal metabolic tumor volume defined by 40% of maximal SUV; N-MTV50% = pretreatment nodal metabolic tumor volume defined by 50% of SUVmax; N-TLG40% = pretreatment nodal TLG defined by 40% of SUVmax; N-TLG50% = pretreatment nodal TLG defined by 50% of SUVmax.